SEC 13F Intelligence

Managers / Q2 2019 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$1.2B
Q2 2019
Positions
37
includes revealed positions
Filings on Record
27
2019–present window
Filed
Aug 14, 2019
original filing

Summary

Boxer Capital, LLC reported $1.2B in U.S.-listed holdings across 37 positions for Q2 2019.

Its largest position, Mirati Therapeutics, represents 15.2% of the portfolio.

Compared with Q1 2019, the fund opened 15 new positions and exited 1.

Portfolio Metrics

Turnover
+11.7%
vs prior filed quarter
Top-10 Concentration
+67.7%
share of reported value
Largest Position
+15.2%
Mirati Therapeutics
New / Exited
15 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 67.7%Other: 20.3%ADR: 12.0%
  • Common Stock · 67.7% · $787M
  • Other · 20.3% · $236M
  • ADR · 12.0% · $140M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPARK THERAPEUTICS INCNEW+600.0K600.0K+$61M$61M
ATRECA INCNEW+1.73M1.73M+$33M$33M
MISTMILESTONE PHARMACEUTICALS INNEW+1.10M1.10M+$30M$30M
AMICUS THERAPEUTICS INCNEW+2.33M2.33M+$29M$29M
ARGXARGENX SENEW+200.0K200.0K+$28M$28M
PREVAIL THERAPEUTICS INCNEW+1.12M1.12M+$15M$15M
ESPERION THERAPEUTICS INC NEREVEALEDNEW+250.0K250.0K+$12M$12M
MERSANA THERAPEUTICS INCNEW+2.08M2.08M+$8M$8M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2019REVEALED

35 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MIRATI THERAPEUTICS INCCOM15.19%$177M1.72M
2ODONATE THERAPEUTICS INCCOM10.61%$123M3.36M
3ONCBEIGENE LTDhistory →SPONSORED ADR9.59%$112M900.0K
4IMMUIMMUNOMEDICS INChistory →COM7.83%$91M6.57M
5SPARK THERAPEUTICS INCCOM5.28%$61M600.0K
6QUREUNIQURE NVhistory →SHS4.13%$48M615.4K
7ESPRESPERION THERAPEUTICS INC NEhistory →COM3.90%$45M975.0K
8PTCTPTC THERAPEUTICS INChistory →COM3.87%$45M1.00M
9DBV TECHNOLOGIES S ASPONSORED ADR3.75%$44M5.30M
10GOSSGOSSAMER BIO INChistory →COM3.58%$42M1.88M
11ATRECA INCCL A COM2.81%$33M1.73M
12MISTMILESTONE PHARMACEUTICALS INhistory →COM2.57%$30M1.10M
13AMICUS THERAPEUTICS INCCOM2.49%$29M2.33M
14ARGXARGENX SEhistory →SPONSORED ADR2.43%$28M200.0K
15MEDICINES COCOM2.35%$27M750.0K
16WVEWAVE LIFE SCIENCES LTDhistory →SHS2.24%$26M1.00M
17RCKTROCKET PHARMACEUTICALS INChistory →COM1.89%$22M1.47M
18ALLAKOS INCCOM1.77%$21M475.0K
19SOLID BIOSCIENCES INCCOM1.72%$20M3.47M
20KURAKURA ONCOLOGY INChistory →COM1.43%$17M844.8K
21PREVAIL THERAPEUTICS INCCOM1.27%$15M1.12M
22GLOBAL BLOOD THERAPEUTICS INCOM1.13%$13M250.0K
23CYMABAY THERAPEUTICS INCCOM0.77%$9M1.25M
24MATINAS BIOPHARMA HLDGS INCCOM0.75%$9M10.19M
25MERSANA THERAPEUTICS INCCOM0.73%$8M2.08M
26IDYAIDEAYA BIOSCIENCES INCCOM0.65%$8M764.3K
27AKROAKERO THERAPEUTICS INCCOM0.65%$8M396.7K
28KDMNKADMON HLDGS INCCOM0.65%$8M3.69M
29MEI PHARMA INCCOM NEW0.63%$7M2.91M
30LJPCLA JOLLA PHARMACEUTICAL COCOM PAR $.0001 20.46%$5M575.0K
31KALVISTA PHARMACEUTICALS INCCOM0.38%$4M200.0K
32KINIKSA PHARMACEUTICALS LTDCOM CL A0.34%$4M290.6K
33VYGRVOYAGER THERAPEUTICS INCCOM0.23%$3M100.0K
34CELLECTAR BIOSCIENCES INCCOM PAR0.17%$2M920.0K
35NOVUS THERAPEUTICS INCCOM0.03%$328,000324.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.